Skip to NavigationSkip to content

Amryt's Lojuxta approved in Brazil to reduce cholesterol in homozygous familial hypercholesterolaemia patients

Published on 09/12/20 at 12:49pm

Brazil’s National Health Surveillance Agency (ANVISA) has moved to authorise Amryt’s Lojuxta (lomitapide) in the country as a treatment for the reduction of low-density lipoprotein cholesterol (LDL-C) in the rare condition homozygous familial hypercholesterolaemia (HoFH). 

The therapy is recommended as an adjunct to a low-fat diet and other lipid-lowering measures in adult HoFH patients, with or without low density lipoprotein (LDL) apheresis.

HoFH is a rare genetic disorder which affects the removal of LDL-C in the body, leading to levels in the blood which can be up to ten times higher than those without the condition. It is associated with the occurrence of “aggressive and premature” cardiovascular disease.

“We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil suffering from HoFH and have approved marketing authorisation for Lojuxta to treat adults with this condition,” remarked Dr Joe Wiley, Chief Executive Officer of Amryt. “Today's news is another milestone in executing our strategy to make Lojuxta available to HoFH patients in need globally.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches